Production and characterization of monoclonal antibodies to human sclerostin

Hybridoma

Volumn 28, Issue 5, 2009, Pages 377-381

  Craig, Theodore A ^a   Sommer, Stacy L ^a   Beito, Thomas G ^b   Kumar, Rajiv ^a,b  

^a Mayo Clinic   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOCYANIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2AK; MONOCLONAL ANTIBODY 2BK; SCLEROSTIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONJUGATE; DISSOCIATION CONSTANT; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL CULTURE; IMMUNIZATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; BONE MORPHOGENETIC PROTEINS; CELLS, CULTURED; DNA PRIMERS; GENETIC MARKERS; HUMANS; MICE; MOLECULAR SEQUENCE DATA; SURFACE PLASMON RESONANCE;

HEXAPODA; MUS;

EID: 70350438265     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2009.0036     Document Type: Article

References (31)

1. ten Dijke P, Krause C, de Gorter DJ, Lowik CW, and van Bezooijen RL: Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am 2008;90(Suppl 1):31-35.
2. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamersma H, Papapoulos SE, ten Dijke P, and Lowik CW: Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004;199:805-814.
3. van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M, Quax PH, Vrieling H, Papapoulos SE, ten Dijke P, and Lowik CW: Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMPstimulated bone formation. J Bone Miner Res 2007;22: 19-28.
4. Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE, Shpektor D, Jonas M, Kovacevich BR, Staehling- Hampton K, Appleby M, Brunkow ME, and Latham JA: Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. Embo J 2003;22:6267-6276.
5. Winkler DG, Sutherland MS, Ojala E, Turcott E, Geoghegan JC, Shpektor D, Skonier JE, Yu C, and Latham JA: Sclerostin inhibition of Wnt-3a-induced C3H10T1=2 cell differentiation is indirect and mediated by bone morphogenetic proteins. J Biol Chem 2005;280:2498-2502.
6. Winkler DG, Yu C, Geoghegan JC, Ojala EW, Skonier JE, Shpektor D, Sutherland MK, and Latham JA: Noggin and sclerostin bone morphogenetic protein antagonists form a mutually inhibitory complex. J Biol Chem 2004;279:36293- 36298.
7. Yavropoulou MP, and Yovos JG: The role of the Wnt signaling pathway in osteoblast commitment and differentiation. Hormones 2007;6:279-294.
8. Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, and Rubin EM: Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 2005;15:928-935.
9. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, et al.: Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001;10:537-543.
10. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C, Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij J, Lindpaintner K, Vickery B, Foernzler D, and Van Hul W: Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 2002;39:91-97.
11. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, and Gillett L: Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knotcontaining protein. Am J Hum Genet 2001;68:577-589.
12. Kusu N, Laurikkala J, Imanishi M, Usui H, Konishi M, Miyake A, Thesleff I, and Itoh N: Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity. J Biol Chem 2003; 278:24113-24117.
13. Lowik CW, and van Bezooijen RL: Wnt signaling is involved in the inhibitory action of sclerostin on BMPstimulated bone formation. J Musculoskelet Neuronal Interact 2006;6:357.
14. Li X, Zhang Y, Kang H, Liu W, Liu P, Zhang J, Harris SE, and Wu D: Sclerostin binds to LRP5=6 and antagonizes canonical Wnt signaling. J Biol Chem 2005;280:19883-19887.
15. Ellies DL, Viviano B, McCarthy J, Rey JP, Itasaki N, Saunders S, and Krumlauf R: Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J Bone Miner Res 2006;21:1738-1749.
16. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, and Bellido T: Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One 2008;3:e2942.
17. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, and Dwyer D: Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008;23:860-869.
18. Baron R, and Rawadi G: Targeting the Wnt=beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007;148:2635-2643.
19. van Bezooijen RL, ten Dijke P, Papapoulos SE, and Lowik CW: SOST=sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine Growth Factor Rev 2005;16:319-327.
20. Craig TA, Benson LM, Bergen HR 3rd, Venyaminov SY, Salisbury JL, Ryan ZC, Thompson JR, Sperry J, Gross ML, and Kumar R: Metal-binding properties of human centrin-2 determined by micro-electrospray ionization mass spectrometry and UV spectroscopy. J Am Soc Mass Spectrom 2006;17:1158-1171.
21. Craig TA, Benson LM, Venyaminov SY, Klimtchuk ES, Bajzer Z, Prendergast FG, Naylor S, and Kumar R: The metal-binding properties of DREAM: evidence for calciummediated changes in DREAM structure. J Biol Chem 2002; 277:10955-10966.
22. Veenstra TD, Tomlinson AJ, Benson L, Kumar R, and Naylor S: Low temperature aqueous electrospray ionization mass spectrometry of noncovalent complexes. J Am Soc Mass Spectrom 1998;9:580-584.
23. Sanger F, Nicklen S, and Coulson AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74:5463-5467.
24. Caruthers MH, Barone AD, Beaucage SL, Dodds DR, Fisher EF, McBride LJ, Matteucci M, Stabinsky Z, and Tang JY: Chemical synthesis of deoxyoligonucleotides by the phosphoramidite method. Methods Enzymol 1987;154:287-313.
25. Caruthers MH, Beaucage SL, Becker C, Efcavitch JW, Fisher EF, Galluppi G, Goldman R, de Haseth P, Matteucci M, McBride L, et al.: Deoxyoligonucleotide synthesis via the phosphoramidite method. Gene Amplif Anal 1983;3: 1-26.
26. Berndt TJ, Craig TA, McCormick DJ, Lanske B, Sitara D, Razzaque MS, Pragnell M, Bowe AE, O'Brien SP, Schiavi SC, and Kumar R: Biological activity of FGF-23 fragments. Pflugers Arch 2007;454:615-623.
27. Poduslo JF, Curran GL, Peterson JA, McCormick DJ, Fauq AH, Khan MA, and Wengenack TM: Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. Biochemistry 2004;43:6064-6075.
28. Ezzat MK, Howell KG, Bahler CK, Beito TG, Loewen N, Poeschla EM, and Fautsch MP: Characterization of monoclonal antibodies against the glaucoma-associated protein myocilin. Exp Eye Res 2008;87:376-384.
29. Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, and Struhl JA: Current Protocols in Molecular Biology. 2006.
30. Harris SA, Enger RJ, Riggs BL, and Spelsberg TC: Development and characterization of a conditionally immortalized human fetal osteoblastic cell line. J Bone Miner Res 1995;10:178-186.
31. Veeman MT, Slusarski DC, Kaykas A, Louie SH, and Moon RT: Zebrafish prickle, a modulator of noncanonical Wnt=Fz signaling, regulates gastrulation movements. Curr Biol 2003; 13:680-685.